DNA Methyltransferase 3B Activity/Inhibitor Screening Assay Core Kit

Business Offer

2017/08/11

United States

Epigenetic inactivation of genes play a critical role in many important human diseases, especially in cancer. A core mechanism for epigenetic inactivation of the genes is methylation of CpG islands in genome DNA. Methylation of CpG islands involves the course in which DNA methyltransferases (Dnmts) transfer a methyl group from S-adenosyl-L-methionine to the fifth carbon position of the cytosines. Four active Dnmts have been identified in mammals. They are named Dnmt1, Dnmt2, Dnmt3A, and Dnmt3B. Dnmt3B has been demonstrated to methylate both unmethylated and hemimethylated DNA equally and is supposed to mediate de novo methylation together with Dnmt1. Increased activation or amount of Dnmt3B is believed to be involved in carcinogenesis, and other genetic and epigenetic diseases. The selective inhibition of Dnmt3B may lead to demethylation and expression of the silenced tumor suppressor genes. Thus, the selective Dnmt3B inhibitors could be a new addition to cancer therapeutic agents.

http://www.creativebiomart.net/dna-methyltransferase-3b-activityinhibitor-screening-assay-core-kit-462734.htm

[RequestAdvantages]

[RequestComments]

399

Caroline Green